Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPULSE trial of empagliflozin in stabilized patients hospitalized for acute heart failure
NL-OMON49418Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) and heart failure (HF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Clinical benefit at 90 days. Started Jun 2020; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)heart failure (HF)
Beyond the preview
Go deeper on NL-OMON49418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49418.